Navigation Links
REMEDIAL II Results on PLC System's RenalGuard® to be Presented at ACC 2011's Late Breaking Clinical Trial Session
Date:4/1/2011

FRANKLIN, Mass., April 1, 2011 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today reported that final results from the REMEDIAL II investigator-sponsored clinical trial of its RenalGuard System™ in Italy are scheduled to be presented at 11:57 a.m. CT on Monday, April 4, 2011, at the American College of Cardiology's (ACC) 60th Annual Scientific Session & Expo in New Orleans, Louisiana. Additionally, PLC will be demonstrating RenalGuard at its booth (#3932) at the conference.

Dr. Carlo Briguori, MD, PhD, Chief, Laboratory of Interventional Cardiology, Clinica Mediterranea, Naples, Italy, and Co-Director of Clinical Research, Laboratory of Interventional Cardiology, San Raffaele Hospital, Milan, Italy, the principal investigator for the REMEDIAL II trial, will present the results during a Late Breaking Clinical Trial session at the conference.

The REMEDIAL II trial is a randomized multi-center clinical trial in Italy designed to provide an assessment of the potential benefits of induced diuresis with automated matched hydration therapy utilizing RenalGuard, compared to a control group, in reducing the incidence of Contrast Induced Nephropathy (CIN) in patients with baseline impairment in renal function undergoing cardiac catheterization procedures and percutaneous coronary interventions.  

About RenalGuard®

RenalGuard is designed to reduce the potentially toxic effects that contrast media can have on the kidneys when it is administered to patients during certain medical imaging procedures. The RenalGuard System consists of a proprietary console and accompanying single-use sets.  With its automated matched fluid replacement capability, RenalGuard is intended to promote and maintain high urine outputs and minimize the risk to patients of over- or under-hydration during image-guided catheterization procedures where contrast media are routinely administered.

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC today focuses on its newest product, RenalGuard, which is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at www.plcmed.com.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the current  clinical trials in Italy and the planned future U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2010, a copy of which is filed with the SEC.

PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc.

Contact:  Mary T. Conway
Conway Communications
617-244-9682
marytconway@comcast.net


'/>"/>
SOURCE PLC Systems Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedClean Technologies Announces 2010 Results
2. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
3. Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
4. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
5. Adeona Reports 2010 Year End Financial Results
6. NeurogesX Reports Fourth Quarter and Year-End 2010 Results
7. Nephros Reports 2010 Fourth Quarter and Full Year Financial Results
8. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
9. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
10. Graymark Healthcare Reports Full Year 2010 Results
11. NOVAVAX Reports Fourth Quarter and 2010 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... --   , Total Sales ... Sales  Clinical sales grow 16% year-over-year  , ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... quarter ended March 31, 2016 and provided an update ... strategy. First Quarter 2016 Revenue Results by ...
(Date:4/27/2016)... SHAWNEE, Kan. , April 27, 2016 /PRNewswire/ ... Martabano , a senior from the University of ... winner of the Bayer Excellence in Communication Award ... veterinary schools, which were awarded a total of ... Over the last four years, Bayer has provided ...
(Date:4/27/2016)... , April 27, 2016 ... reach USD 2.06 billion by 2022, according to ... Increasing consumer awareness towards a healthy lifestyle is ... seven years.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... coupled with rising health treatment expenditure has urged ...
Breaking Medicine Technology:
(Date:5/1/2016)... ... May 02, 2016 , ... Avid ... Jimi Hendrix Merriweather Post Pavilion in Columbia, Maryland concert posters. Dail Beeghley hit ... concert was held on August 16. According to Hawley, “The Pavilion was built ...
(Date:5/1/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... and a guide on their website, http://www.womensexcellence.com that gives new mothers ... of:, · Warning signs and when to call, · Adjusting to baby postpartum, ...
(Date:5/1/2016)... ... 01, 2016 , ... Outdoor Growing Bans Are Sweeping California, which states are ... law in the hands of the local communities to decide each county’s fate ... counties to vote on growing regulations by 3/1/2016 or be forced to follow how ...
(Date:4/30/2016)... ... ... Serenity Recovery, a substance abuse treatment center located in Central Michigan that takes ... of the more popular of their optional courses, the Yoga Class. With footage from ... the Yoga class instructor, this video is available for viewing on the Serenity Recovery ...
(Date:4/30/2016)... , ... April 30, 2016 , ... ... Carol Francis Talk Radio with Hypnotherapist, Mary O'Maley. What is hypnosis and ... habit control (substances, smoking, weight control), pain relief (chronic and acute), birthing processes ...
Breaking Medicine News(10 mins):